Scientists test 'Living Drug' to reboot immune system in tough lupus cases

NCT ID NCT06189157

First seen Nov 01, 2025 · Last updated Apr 22, 2026 · Updated 22 times

Summary

This early-stage trial is testing a new cell therapy called MB-CART19.1 for adults with severe lupus that hasn't responded to standard treatments. Doctors will modify a patient's own immune cells (T cells) to target and reduce the harmful B cells thought to drive lupus. The main goals are to find a safe dose and see if this one-time treatment can put the disease into remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Otto-von-Guericke-Universität Magdeburg

    RECRUITING

    Magdeburg, Germany

    Contact

    Contact

  • Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II

    RECRUITING

    Tübingen, Germany

    Contact

    Contact

  • Universitätsklinikum Erlangen, Medizinische Klinik 3

    NOT_YET_RECRUITING

    Erlangen, Germany

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.